The conduct and oversight of the progress of trials and safety of participants is achieved in many ways through development, review and performance throughout the lifecycle of the research study. In addition to the important role of the principal and co-investigator(s), the research team(s) and the individual Cancer Center Disease Programs to this endeavor, the Clinical Protocol Scientific Review and Monitoring Committee (CPSRMC) of the Cancer Center is at the core of this process. The scope and responsibilities of this Committee have evolved over time to provide rigorous and supportive review and monitoring of clinical investigations within the Cancer Center. Initially established in 1992 as the Scientific Review Board and following the then current NCI guidelines, the committee initially focused on scientific validity, study design and appropriates of statistical endpoints of protocols that did not have external peer review. Based on a desire to extend this review to all protocols in the Cancer Center, the scope and responsibilities of the committee were expanded in 1995 with a new charter and newly appointed members. More recently additional changes to enhance the process include a requirement for submission to the CPSRMC of a programmatic protocol review;adoption of a risk-based model for monitoring of clinical trials and strengthening the committee membership with additional senior researchers. In its current functions the CPSRMC reviews the scientific rationale, feasibility, study and biostatistical designs, and provides oversight to the progress of all institutional protocols to ensure adherence to initial study design, timely accruals, stopping criteria are followed and that patient safety is maintained. In addition, the CPSRMC is empowered to modify study conduct or close studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-34W1
Application #
8738020
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z)
Project Start
2012-03-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
34
Fiscal Year
2013
Total Cost
$801
Indirect Cost
$343
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Wu, Jianrong (2015) Power and sample size for randomized phase III survival trials under the Weibull model. J Biopharm Stat 25:16-28
Serinagaoglu, Yelda; Paré, Joshua; Giovannini, Marco et al. (2015) Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development. Dev Biol 398:97-109
Kimberg, Cara I; Klosky, James L; Zhang, Nan et al. (2015) Predictors of health care utilization in adult survivors of childhood cancer exposed to central nervous system-directed therapy. Cancer 121:774-82
Bhojwani, Deepa; McCarville, Mary B; Choi, John K et al. (2015) The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol 168:845-53
Chamdine, Omar; Gaur, Aditya H; Broniscer, Alberto (2015) Effective treatment of cerebral mucormycosis associated with brain surgery. Pediatr Infect Dis J 34:542-3
Karol, Seth E; Coustan-Smith, Elaine; Cao, Xueyuan et al. (2015) Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol 168:94-101
Chan, W K; Suwannasaen, D; Throm, R E et al. (2015) Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia 29:387-95
Gawade, Prasad L; Oeffinger, Kevin C; Sklar, Charles A et al. (2015) Lifestyle, distress, and pregnancy outcomes in the Childhood Cancer Survivor Study cohort. Am J Obstet Gynecol 212:47.e1-10
Momani, Tha'er G; Mandrell, Belinda N; Gattuso, Jami S et al. (2015) Children's perspective on health-related quality of life during active treatment for acute lymphoblastic leukemia: an advanced content analysis approach. Cancer Nurs 38:49-58
Dodd, K; Nance, S; Quezada, M et al. (2015) Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity. Oncogene 34:1312-22

Showing the most recent 10 out of 5513 publications